Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 95

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 95
---
, in no case shall the Purchaser, the Company or any other person be required to recognize                                                                                                                                   
 Dissenting Shareholders as holders of Common Shares in respect of which Dissent Rights have been validly exercised after the completion of the transfer under Section 2.3(g), and the names of such Dissenting Shareholders shall be removed from 
 the Company’s central securities register in                                                                                                                                                                                                      |

A-7

| respect of those Common Shares in respect which Dissent Rights have been validly exercised at the same time as the event described in Section 2.3(g) occurs. |

| (c) | In addition to any other restrictions under Chapter XIV – Division I of the QBCA, none of the following                                                                                                                                    
 shall be entitled to exercise Dissent Rights: (i) holders of Incentive Securities, (ii) the holder of the Warrant, and (ii) holders of Common Shares who vote or have instructed a proxyholder to vote such Common Shares in favour of the 
 Arrangement Resolution.                                                                                                                                                                                                                    |

ARTICLE 4 CERTIFICATES AND PAYMENTS

| 4.1 | Payment and Delivery of Consideration |

| (a) | The Company shall, following receipt of the Final Order and final agreement on the Closing Cash Calculation,                                                                                                                                           
 and at least one Business Day prior to the Effective Date, provide or cause to be provided to, the Depositary sufficient funds to satisfy the aggregate Cash Amount and Incentive Securities Cash Balance payable to the Shareholders pursuant to this 
 Plan of Arrangement, which funds shall be held by the Depositary in escrow as agent and nominee for such Shareholders (the terms and conditions of such escrow to be satisfactory to the Company and the Purchaser, each acting reasonably).           |

| (b) | The Purchaser shall, following receipt of the Final Order, and at least one Business Day prior to the Effective                                                                                                                                        
 Date, provide or cause to be provided to the Depositary CVRs to satisfy the aggregate number of CVRs payable in accordance herewith, which CVRs shall be held by the Depositary in escrow as agent and nominee for such Securityholders (the terms and 
 conditions of such escrow to be satisfactory to the Company and the Purchaser, each acting reasonably).                                                                                                                                                |

| (c) | Upon surrender to the Depositary for cancellation of a certificate or DRS Advice which immediately prior to the                                                                                                                                 
 Effective Time represented outstanding Common Shares that were transferred pursuant to Section 2.3(f)